American society of clinical oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3333-3355

  Hensley, Martee L ^a   Schuchter, Lynn M ^a   Lindley, Celeste ^a   Meropol, Neal J ^a   Cohen, Gary I ^a   Broder, Gail ^a   Gradishar, William J ^a   Green, Daniel M ^a   Langdon Jr , Robert J ^a   Brian Mitchell, R ^a   Negrin, Robert ^a   Szatrowski, Ted P ^a   Tate Thigpen, J ^a   VonHoff, Daniel ^a   Wasserman, Todd H ^a   Winer, Eric P ^a   Pfister, David G ^a  

^a Health Services Research Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FUROSEMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; MITOXANTRONE; ONDANSETRON; PACLITAXEL; PARATHYROID HORMONE; RAZOXANE; SODIUM CHLORIDE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIURESIS; DRUG COST; DRUG EFFICACY; HEART PROTECTION; HEMORRHAGIC CYSTITIS; HUMAN; HYPOCALCEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SARCOMA; SURVIVAL; THROMBOCYTOPENIA; URINARY TRACT DISEASE; UROTHELIUM; VOMITING; XEROSTOMIA;

EID: 0032872127     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3333     Document Type: Review

References (113)

1. ASCO Ad Hoc Colony-Stimulating Factors Guidelines Expert Panel: American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
2. American Society of Clinical Oncology: American Society of Clinical Oncology update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 14:1957-1960, 1996
3. Canadian Medical Association: The Canadian task force on the periodic health examination. Can Med Assoc J 121:1193-1254, 1979
4. Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95:2S-4S, 1989 (suppl 2)
5. Cook DL, Guyatt GH, Laupacis A, et al: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102:3055-311S, 1992 (suppl 4)
6. American Society of Clinical Oncology Outcomes Working Group: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679, 1996
7. Brock N, Pohl J, Stekar J: Studies on the urotoxicity of oxazaphosphorine cytostatic and its prevention: 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur J Cancer Clin Oncol 17:1155-1163, 1981
8. Brock N, Stekar J, Pohl J, et al: Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide, and sufosfamide. Arzneimittelforschung 29:659-661, 1979
9. Teufel G, Pfleiderer A: Ifosfamid im bergleich zu endoxan bei frotgeschrittenen ovarilkarzinomin. Geburtshilfe Frauenheilkd 36:274-279, 1976
10. Utracka-Hutka B, Utracka-Hutka B: Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan. Nowotwory 30:377-383, 1980
11. Van Dyk JJ, Falkson HC, Van der Merwe, et al: Unexpected toxicity in patients with ifosfamide. Cancer Res 32:921-924, 1972
12. Creaven PJ, Allen LM, Cohen MH, et al: Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109427). Cancer Treat Rep 60:445-449, 1976
13. Atkinson K, Biggs JC, Golovsky D, et al: Bladder irrigation does not prevent haemorrhagic cystitis in bone marrow transplant recipients. Bone Marrow Transplant 7:351-354, 1991
14. Shepard JD, Pringle LE, Barnett MJ, et al: Mesna versus hyperhydration for the prevention of cyclophosphamide-induced herrotthagic cystitis in bone marrow transplantation. J Clin Oncol 9:2016-2020, 1991
15. Brugieres L, Haretmann O, Travagli JP, et al: Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: Incidence, clinical course, and outcome. J Clin Oncol 7:194-199, 1989
16. Hows JM, Mehta A, Ward L, et al: Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: A prospective randomized study. Br J Cancer 50:753-756, 1984
17. Haselberger MB, Schwinghammer TL: Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacother 29:918-921, 1995
18. Watson NA, Notley RG: Urologie complication of cyclophosphamide. Br J Urol 45:606-9, 1973
19. Phillips FS, Sternberg SS, Cronin AP, et al: Cyclophosphamide and urinary bladder toxicity. Cancer Res 21:1577-1589, 1961
20. Allen LM, Creaven PJ, Nelson RL: Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat Rep 60:451-458, 1976
21. Nelson RI, Allen LM, Creaven PJ: Pharmacokinetics of divided-dose ifosfamide. Clin Pharmacol Ther 19:365-370, 1976
22. D'Incalci M, Bolis G, Facchinetti T, et al: Decreased half life of cyclophosphamide in patients under continual treatment. Eur J Cancer 15:7-10, 1979
23. Graham MI, Shaw IC, Souham RL, et al: Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother Pharmacol 10:192-193, 1983
24. Kurowski V, Wagner T: Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Cancer Chemother Pharmacol 39:431-439, 1997
25. Brock N, Pohl J, Stekar J, et al: Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention: III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 18:1377-1387, 1982
26. Dechant KL, Brogden RN, Pilkington T, et al: Ifosfamide/mesna: A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42:428-467, 1991
27. Brade WP, Herdrich K, Klein HO: Ifosfamide: Dosing and scheduling, in Burkert N (ed): Contributions to Oncology. Basel, Switzerland, Karger, 1987, pp 22-52
28. Klein HA, Wickramanayake P, Coerper C, et al: High-dose ifosfamide and mesna as continuous infusion over five days: A phase I/II trial. Intl Symposium on Mesna and Mitoxanan: Significant Progress in the Treatment of Cancer, March 16-18, 1983, Coventry England. Cancer Treat Rev 10:167-173, 1983 (suppl A)
29. James CA, Mant TGK, Rogers HJ: Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol 23:561-568, 1987
30. Goren MP, Anthony LB, Hande KR, et al: Pharmacokinetics of an intravenous-oral versus intravenous mesna regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 16:616-621, 1998
31. Scheef W, Klien HO, Brock N, et al: Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: Preliminary results. Cancer Treat Rep 63:501-505, 1979
32. Scheef W: Clinical experience with mesna (Uromitexan), in Proceedings of the 12th International Congress of Chemotherapy, 1980 (abstr 173)
33. Fukuoka M, Negoro S-I, Masuda N, et al: Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 117:473-478, 1991
34. Scheef W, Soemer G: The treatment of solid malignant tumours with holoxan and uromitexan, in Burkert N, Nagel GA (eds): Contributions to Oncology. Basel, Switzerland, Karger, 1980, pp 21-24
35. Antman KH, et al: Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69:499-504, 1985
36. Scheulen ME, et al: Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: Results of a clinical phase II-study with 151 patients. Cancer Treat Rep 10:93-101, 1983 (suppl A)
37. Neiderle N, et al: Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. Cancer Treat Rev 10:129-35, 1983
38. Stuart-Harris RC, et al: High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11:69-72, 1983
39. Klein HO, et al: Experimental and clinical studies on the significance of the uroprophylactic sodium 2-mercaptoethane sulfonate (Uromitexan) in cytostatic therapy with oxazaphosphorines, in Burkert N (ed): Contributions to Oncology. Basel, Switzerland, Karger, 1980, pp 25-39
40. Kemeny N, et al: Phase II trial of ifosfamide and mesna in advanced colorectal cancer. Cancer Treat Rep 71:663-664, 1987
41. Andriole GL, et al: The efficacy of mesna (2-mercaptoethane sodium sulfonate) as an uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J Clin Oncol 5:799-803, 1987
42. Sladek NE, Smith PC, Bratt PM, et al: Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity. Cancer Treat Rep 66:1889-1900, 1982
43. Sakurai M, Saijo N, Shinkai T, et al: The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Jpn J Clin Oncol 16:153-156, 1986
44. Elias A, Eder JP, Skea T, et al: High dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 8:170-178, 1990
45. LeCesne A, Antoine E, Spielmann M, et al: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608, 1995
46. Turrill M, Spicer DV, Kelley AS, et al: Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma. Cancer Invest 13:160-164, 1995
47. Katz A, Epelman S. Anelli A, et al: A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: Sustained efficiency and simplified administration. J Cancer Res Clin Oncol 121:128-131, 1995
48. Vose JM, Reed EC, Pippert GC, et al: Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: A randomized trial. J Clin Oncol 11:1306-1310, 1993
49. Cortes EP, Lutman G, Wanka J, et al: Adriamycin (NSC-123127) cardiotoxicity: A clinicopathologic correlation. Cancer Chemother Rep 6:215-225, 1975
50. Lefrak EA, Pitha J, Rosenheim S, et al: Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314, 1973
51. Weiss AJ, Manthel RW: Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule with particular reference to lack of cardiac toxicity. Cancer 40:2046-2052, 1977
52. Weiss AJ, Metter GE, Fletcher WS, et al: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60:813-822, 1976
53. VonHoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
54. Pratt CB, Ransom JL, Evans WE: Age-related cardiotoxicity in children. Cancer Treat Rep 62:1381-1385, 1978
55. Smith PJ, Ekert H, Waters KD, et al: High incidence of cardiomyopathy in children treated with adriamycin and DTIC in combination chemotherapy. Cancer Treat Rep 61:1736-1738, 1977
56. Prout MN, Richards MJS, Chung KJ, et al: Adriamycin cardiotoxicity in children. Cancer 39:62-65, 1977
57. Bhanot P, Cushing B, Phillipart A, et al: Hepatic irradiation and adriamycin cardiotoxicity. J Pediatr 95:561-563, 1979
58. Pinkel D, Camitta B, Kun L, et al: Doxorubicin cardiomyopathy in children with left-sided Wilms' tumor. Med Pediatr Oncol 10:483-488, 1982
59. Henderson IC, Sloss LJ, Jaffe N, et al: Serial studies of cardiac function in patients receiving adriamycin. Cancer Treat Rep 62:923-929, 1978
60. Hutchinson RJ, Bailey C, Wood D, et al: Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients. Cancer Treat Rep 62:907-910, 1978
61. Alexander J, Dainiak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278-283, 1979
62. Druck MN, Gulenchyn KY, Evans WK, et al: Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 53:1667-1674, 1984
63. Schwartz RG, McKenzie WB, Alexander J, et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiography. Am J Med 82:1109-1118, 1987
64. Bristow MR, Manson JW, Billingham ME, et al: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 88:168-175, 1978
65. Torti FM, Bristow MR, Howes AE, et al: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Intern Med 99:745-749, 1983
66. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982
67. Bristow MR, Lopez MB, Mason JW, et al: Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 50:32-41, 1982
68. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
69. Sorenson K, Levitt G, Bull C, et al: Amthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol 15:61-68, 1997
70. Sorenson K, Levitt G, Sebag-Montefiore D, et al: Cardiac function in Wilms'tumor survivors. J Clin Oncol 13:1546-1556, 1995
71. Kadadekar AP, Sandor GGS, Fryer C, et al: Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients. Med Pediatr Oncol 28:22-26, 1997
72. Postma A, Bink-Boelkens MTE, Beaufort-Krol GCM, et al: Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 26:230-237, 1996
73. Silber JH, Jakacki RI, Larsen RL, et al: Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 21:477-479, 1993
74. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
75. Steinherz LJ, Steinherz PG, Tan CTC, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991
76. Speyer JL, Green MD, Kramer E, et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745-752, 1988
77. Zinecard (dexrazoxane for injection) [package insert]. Columbus, Ohio, Pharmacia, Inc, 1994
78. Hochster H, Liebes L, Wadler S, et al: Pharmacokenetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725-1730, 1992
79. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992
80. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
81. Swain SM, Whaley FS, Gerber MC, et al: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333-1340, 1997
82. Russell L, Basser M, Motty S, et al: Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 12:1659-1666, 1994
83. Lopez M, Vici P, Di Lauro L, et al: Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16:86-92, 1998
84. Wexler LH, Andrich MP, Venzon D, et al: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362-372, 1996
85. Venturini M, Michelotti A, Del Mastro L, et al: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14:3112-3120, 1996
86. Schuchter LM, Glick J: The Current status of WR-2721 (Amifostine): A chemotherapy and radiation therapy protector. Biologic Ther Cancer 3:1-10, 1993
87. Coleman N, Bump E, Kramer R: Chemical modifiers of cancer treatment. J Clin Oncol 6:709-733, 1988
88. Calabro-Jones P, Aguilera J, Ward J, et al: Uptake of amifostine derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 48:3634-3640, 1988
89. Yuhas JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-Aminopropylamino)-ethylphosphorothioic acid. Cancer Res 40:1519-1524, 1980
90. Blumberg AL, Nelson DF, Gramkowski M, et al: Clinical trials of WR-2721 with radiation therapy, Int J Radiat Oncol Biol Phys 8:561-563, 1982
91. Glover D, Riley L, Carmichael K, et al: Hypocalcemia and inhibition of parathyroid hormone secretion after administration of amifostine (a radioprotective and chemoprotective agent). N Engl J Med 309:117-1141, 1983
92. Shaw LM, Turrisi ATI, Glover DJ, et al: Human pharmacokinectics of WR-2721. Int J Radiat Oncol Biol Phys 12:1501-1504, 1986
93. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
94. Glover D, Glick J, Weiler C, et al: WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol 5:574-578, 1987
95. Schiller JH: High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin Oncol 23:78-82, 1996
96. Dorr RT, Von Hoff DD (eds): Cancer Chemotherapy Handbook (ed 2), Norwalk, CT, Appleton & Lange, 1994
97. Bennett CL, Golub RM, Calhoun EA, et al: Cost-utility assessment of amifostine as first-line therapy for ovarian cancer. Int J Gynecol Cancer 8:64-72, 1998
98. Glover D, Glick J, Weiler C, et al: Phase I trials of amifostine and cis-platinum. Int J Radiat Oncol Biol Phys 10:1781-1784, 1984
99. Mollman JE, Glover DJ, Hogan WM, et al: Cisplatin neuropathy, risk factors, prognosis and protection by WR-2721. Cancer 61:2192-2195, 1988
100. Calvert AH, Vewell DR, Gumbrell LH, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
101. Glover D, Glick JH, Weiler C, et al: WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J Clin Oncol 4:584-588, 1986
102. Capizzi RL, Scheffler BJ, Schein PS: Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 72:3495, 1993
103. Budman DR, Rosner GL, Lichtman SM, et al: Evaluation of amifostine as a chemoprotective agent in combination with cyclophosphamide and molgramostim (GM-CSF). Cancer Ther 1:164-167, 1998
104. Budd GT, Ganapathi R, Adelstein DJ, et al: Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 80:1134-1140, 1997
105. Rowinsky EK, Chaudhry V, Cornblath DR, et al: Neurotoxicity of Paclitaxel. Monogr Natl Cancer Inst 15:107-115, 1993
106. Taylor CW, Wang L, List AF, et al: Amifostine protects normal tissue from paclitaxel toxicity while cytotoxicity against tumor cells is maintained. Eur J Cancer (in press)
107. Tinwell H, Ashby J: Genetic toxicity and potential carcinogenicity of paclitaxel. Carcinogenesis 15:1499-1501, 1994
108. DiPaola R, Rodriguez R, S G, et al: Amifostine and dose intense paclitaxel in patients with advanced malignancies. Cancer Ther 1:11-17, 1998
109. Schuller J, Czejka M, Pietrzak C, et al: Influence of the cytoprotective agent amifostine (AMI) on pharmacokinetics (PK) of paclitaxel (PAC) and Taxotere (TXT). Proc Am Soc Clin Oncol 16:224a, 1997 (abstr 785)
110. Mossman KL: Frequent short-term oral complications of head and neck radiotherapy. Ear Nose Throat J 73:316-320, 1994
111. Sauer R, Brizel D, Wannenmacher M, et al: Randomized phase III trial of radiation ± amifostine in patients with head and neck cancer. Proc Am Soc Clin Oncol 18:392a, 1999 (abstr 1516)
112. Liu T, Liu Y, He S, et al: Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 69:2820-2825, 1992
113. Buntzel J, Kuttner K, Frohlich D, et al: Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9:505-509, 1998